Anti-cancer nuclear hormone receptor-targeting compounds
US11952349B2 · kind B2 · utility
2Cited by
21References
10Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 12, 2020 |
| Grant date | Apr 9, 2024 |
| Priority date | — |
| Expiry date | Nov 12, 2040 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07J71/0047
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
The disclosure relates to anti-cancer compounds derived from a payload which binds to poly(ADP-ribose) polymerase (PARP) and a nuclear steroid-targeting epitope (B of Formula I), which components are covalently linked via a linker, to products containing the same, as well as to methods of their use and preparation.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.